Indian J Pharm Close
 

Table 11: Question 4 (i): What is the most appropriate choice of therapy for HR +ve/ Her2 −ve breast cancer post‑menopausal patients with newly diagnosed stage IV de novo disease and no visceral crisis?

Table 11: Question 4 (i): What is the most appropriate choice of therapy for HR +ve/ Her2 −ve breast cancer post‑menopausal patients with newly diagnosed stage IV <i>de novo</i> disease and no visceral crisis?